ResApp Health Limited announced that it has received Institutional Review Board ("IRB") approval to modify its US-based SARS-CoV2 ("COVID-19") clinical study, COVID-Cough, to allow for recruitment at in-person COVID-19 testing clinics. ResApp has partnered with Covid Clinic to recruit 100 COVID-19 PCR-confirmed subjects at seven of its COVID-19 testing clinics in California. Covid Clinic is a nationwide network of COVID-19 testing sites with well over 100 locations in the US and has extensive experience in performing COVID-19 research studies. The US-based COVID-Cough pilot clinical study (clinicaltrials.gov: NCT04864535) aims to secure data to train an algorithm to identify COVID-19 through cough sounds recorded on a smartphone, using a gold standard PCR pathology test as a reference standard. The COVID-Cough study aims to recruit up to 1,500 subjects in the US with recruitment in the study expected to complete mid-December 2021.